CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 960 enrolled
Drug / intervention
Paracetamol 1000 mg SR tablets +2 moredrug
Likely dose
Paracetamol 1000 mg SR tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02311881
NCT02311881Phase 3Completed

An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects With Osteoarthritis

GlaxoSmithKline·interventional·Posted Dec 9, 2014·Updated Apr 7, 2017

In Brief

A Phase 3 clinical trial evaluating Paracetamol 1000 mg SR tablets, Paracetamol 665 mg SR tablets, and 1 other intervention for Pain. Completed, enrolled 960 participants across 56 sites.

Detailed Summary

The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 9, 2014
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.6 years ago

Interventions

Paracetamol 1000 mg SR tabletsdrug

Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.

Paracetamol 665 mg SR tabletsdrug

Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.

Placebodrug

Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.